CD4+/CD56+ hematodermic tumor: The features of an evolving entity and its relationship to dendritic cells

American Journal of Clinical Pathology

Volumn 127, Issue 5, 2007, Pages 687-700

  Herling, Marco ^a   Jones, Dan ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Box 72 ^*  (United States)

Author keywords

Blastic NK cell lymphoma; CD4+ CD56+ hematodermic tumor; DC2; Dendritic cells; TCL1

Indexed keywords

CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ANTIGEN EXPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORPHOLOGY; CANCER RELAPSE; CELL ACTIVITY; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DENDRITIC CELL; DISEASE COURSE; HISTOGENESIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MEDICAL SOCIETY; MYELOID LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; NATURAL KILLER CELL; NOMENCLATURE; ONCOGENE; PRIORITY JOURNAL; SKIN TUMOR; T CELL LEUKEMIA; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; TUMOR CLASSIFICATION; BONE MARROW CELL; CUTANEOUS T CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; PATHOLOGY; REVIEW;

ANTIGENS, CD4; ANTIGENS, CD56; DENDRITIC CELLS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL, CUTANEOUS; MYELOID CELLS; SKIN NEOPLASMS;

EID: 34249732606     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/FY6PK436NBK0RYD4     Document Type: Conference Paper

References (123)

1. Gattei V, Carbone A, Zagonel V, et al. Expression of natural killer antigens in a subset of "non-T, non-B lymphoma/leukaemia with histiocytic features." Br J Haematol. 1990;76:444-448.
2. Tauchi T, Ohyashiki K, Ohyashiki JH, et al. CD4+ and CD56+ acute monoblastic leukemia. Am J Hematol. 1990;34:228-229.
3. Brody JP, Allen S, Schulman P, et al. Acute agranular CD4-positive natural killer cell leukemia: comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. Cancer. 1995;75:2474-2483.
4. Kameoka J, Ichinohasama R, Tanaka M, et al. A cutaneous agranular CD2- CD4+ CD56+ "lymphoma": report of two cases and review of the literature. Am J Clin Pathol. 1998;110:478-488.
5. Bagot M, Bouloc A, Charue D, et al. Do primary cutaneous non-T non-B CD4+CD56+ lymphomas belong to the myelomonocytic lineage? [letter]. J Invest Dermatol. 1998;111:1242-1244.
6. Petrella T, Dalac S, Maynadie M, et al, for the Groupe Français d'Etude des Lymphomes Cutanes (GFELC). CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Am J Surg Pathol. 1999;23:137-146.
7. Kimura S, Kakazu N, Kuroda J, et al. Agranular CD4+CD56+ blastic natural killer leukemia/lymphoma. Ann Hematol. 2001;80:228-231.
8. Chan JKC, Jaffe ES, Ralfikiaer E. Blastic NK-cell lymphoma. In: Jaffe ES, Harris N, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:214-215. World Health Organization Classification of Tumours.
9. DiGiuseppe JA, Louie DC, Williams JE, et al. Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. Am J Surg Pathol. 1997;21:1223-1230.
10. Bayerl MG, Rakozy CK, Mohamed AN, et al. Blastic natural killer cell lymphoma/leukemia: a report of seven cases. Am J Clin Pathol. 2002;117:41-50.
11. Falcao RP, Garcia AB, Marques MG, et al. Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity. Leuk Res. 2002;26:803-807.
12. Estalilla OC, Manning JT, Medeiros LJ. TdT-positive blastoid natural killer (NK)-cell lymphoma/leukemia: a report of four cases [abstract]. Mod Pathol. 2000;13:148A.
13. Ginarte M, Abalde MT, Peteiro C, et al. Blastoid NK cell leukemia/lymphoma with cutaneous involvement. Dermatology. 2000;201:268-271.
14. Knudsen H, Gronbaek K, thor Straten P, et al. A case of lymphoblastoid natural killer (NK)-cell lymphoma: association with the NK-cell receptor complex CD94/NKG2 and TP53 intragenic deletion. Br J Dermatol. 2002;146:148-153.
15. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97:3210-3217.
16. Anargyrou K, Paterakis G, Boutsis D, et al. An unusual case of CD4+ CD7+ CD56+ acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia. Eur J Haematol. 2003;71:294-298.
17. Khoury JD, Medeiros LJ, Manning JT, et al. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer. 2002;94:2401-2408.
18. Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99:1556-1563.
19. Petrella T, Comeau MR, Maynadie M, et al. "Agranular CD4+ CD56+ hematodermic neoplasm" (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26:852-862.
20. Kato N, Yasukawa K, Kimura K, et al. CD2- CD4+ CD56+ hematodermic/ hematolymphoid malignancy. J Am Acad Dermatol. 2001;44:231-238.
21. Jacob MC, Chaperot L, Mossuz P, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88:941-955.
22. Giagounidis AA, Heinsch M, Haase S, et al. Early plasmacytoid dendritic cell leukemia/lymphoma coexpressing myeloid antigens. Ann Hematol. 2004;83:716-721.
23. Herling M, Teitell MA, Shen RR, et al. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 2003;101:5007-5009.
24. Prasthofer EF, Prchal JT, Grizzle WE, et al. Plasmacytoid T-cell lymphoma associated with chronic myeloproliferative disorder. Am J Surg Pathol. 1985;9:380-387.
25. Vermi W, Facchetti F, Rosati S, et al. Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. Am J Surg Pathol. 2004;28:585-595.
26. Mori KL, Egashira M, Oshimi K. Differentiation stage of natural killer cell - lineage lymphoproliferative disorders based on phenotypic analysis. Br J Haematol. 2001;115:225-228.
27. Almasri NM, Mitchell D, Braylan RC. Blastic natural killer cell [letter]. Am J Surg Pathol. 1999;23:991-992.
28. Tamura H, Ogata K, Mori S, et al. Lymphoblastic lymphoma of natural killer cell origin, presenting as pancreatic tumour. Histopathology. 1998;32:508-511.
29. Koita H, Suzumiya J, Ohshima K, et al. Lymphoblastic lymphoma expressing natural killer cell phenotype with involvement of the mediastinum and nasal cavity. Am J Surg Pathol. 1997;21:242-248.
30. Grouard G, Rissoan MC, Filgueira L, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med. 1997;185:1101-1111.
31. Wang YH, Liu YJ. Mysterious origin of plasmacytoid dendritic cell precursors. Immunity. 2004;21:1-2.
32. Pelayo R, Welner R, Perry SS, et al. Lymphoid progenitors and primary routes to becoming cells of the immune system. Curr Opin Immunol. 2005;17:100-107.
33. Reichard KK, Burks EJ, Foucar MK, et al. CD4(+) CD56(+) lineage - negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol. 2005;29:1274-1283.
34. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123:662-675.
35. Rossi JG, Felice MS, Bernasconi AR, et al. Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome. Leuk Lymphoma. 2006;47:715-725.
36. Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32:637-646.
37. Bekkenk MW, Jansen PM, Meijer CJ, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004;15:1097-1108.
38. Penven K, Macro M, Salaun V, et al. Skin manifestations in CD4+, CD56+ malignancies. Eur J Dermatol. 2003;13:161-165.
39. Petrella T, Meijer CJ, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol. 2004;122:307-313.
40. Jaye DL, Geigerman CM, Herling M, et al. The pattern of expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ blastoid tumors. Mod Pathol. 2006;19:1555-1562.
41. Pekarsky Y, Koval A, Hallas C, et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A. 2000;97:3028-3033.
42. Laine J, Kunstle G, Obata T, et al. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6:395-407.
43. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91:12530-12534.
44. Said JW, Hoyer KK, French SW, et al. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest. 2001;81:555-564.
45. Narducci MG, Pescarmona E, Lazzeri C, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 2000;60:2095-2100.
46. Teitell M, Damore MA, Sulur GG, et al. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proc Natl Acad Sci U S A. 1999;96:9809-9814.
47. Hoyer KK, Herling M, Bagrintseva K, et al. T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol. 2005;175:864-873.
48. Herling M, Khoury JD, Washington LT, et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004;104:328-335.
49. Suzuki R, Nakamura S, Suzumiya J, et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer. 2005;104:1022-1031.
50. Ito T, Inaba M, Inaba K, et al. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol. 1999;163:1409-1419.
51. Mohty M, Jarrossay D, Lafage-Pochitaloff M, et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood. 2001;98:3750-3756.
52. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5:919-923.
53. Res PC, Couwenberg F, Vyth-Dreese FA, et al. Expression of pT́ mRNA in a committed dendritic cell precursor in the human thymus. Blood. 1999;94:2647-2657.
54. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90:3245-3287.
55. Leroux D, Mugneret F, Callanan M, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogenetique Hematologique. Blood. 2002;99:4154-4159.
56. Hallermann C, Middel P, Griesinger F, et al. CD4+ CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmocytoid dendritic cells. Eur J Dermatol. 2004;14:317-322.
57. Bernasconi P, Boni M, Cavigliano PM, et al. Molecular genetics of acute myeloid leukemia. Ann N Y Acad Sci. 2002;963:297-305.
58. Rigolin GM, Cuneo A, Roberti MG, et al. Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization. Haematologica. 1997;82:25-30.
59. Liu XY, Atkins RC, Feusner JH, et al. Blastic NK-cell-like lymphoma with T-cell receptor gene rearrangement. Am J Hematol. 2004;75:251-253.
60. Aoyama Y, Yamane T, Hino M, et al. Blastic NK-cell lymphoma/leukemia with T-cell receptor gamma rearrangement. Ann Hematol. 2001;80:752-754.
61. Knapp W, Stockinger H, Majdic O. Antibody-defined cell surface molecules of the immune system. Curr Opin Immunol. 1989;2:884-891.
62. Di Bona E, Sartori R, Zambello R, et al. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 2002;87:250-256.
63. Delgado J, Morado M, Jimenez MC, et al. CD56 expression in myeloperoxidase-negative FAB M5 acute myeloid leukemia. Am J Hematol. 2002;69:28-30.
64. Kuwabara H, Nagai M, Yamaoka G, et al. Specific skin manifestations in CD56 positive acute myeloid leukemia. J Cutan Pathol. 1999;26:1-5.
65. Kaddu S, Beham-Schmid C, Zenahlik P, et al. CD56+ blastic transformation of chronic myeloid leukemia involving the skin. J Cutan Pathol. 1999;26:497-503.
66. Garnache-Ottou F, Chaperot L, Biichle S, et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 2005;105:1256-1264.
67. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999;283:1183-1186.
68. Romagnani C, Della Chiesa M, Kohler S, et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol. 2005;35:2452-2458.
69. Lennert K, Kaiserling E, Muller-Hermelink HK. T-associated plasma-cells [letter]. Lancet. 1975;1:1031-1032.
70. Facchetti F, de Wolfe-Peeters C, van den Oord JJ, et al. Immunohistochemical visualization of plasmacytoid T cells in paraffin sections [letter]. Hum Pathol. 1987;18:1300.
71. Facchetti F, De Wolf-Peeters C, van den Oord JJ, et al. Plasmacytoid monocytes (so-called plasmacytoid T cells) in Hodgkin's disease. J Pathol. 1989;158:57-65.
72. Facchetti F, de Wolf-Peeters C, Mason DY, et al. Plasmacytoid T cells: immunohistochemical evidence for their monocyte/macrophage origin. Am J Pathol. 1988;133:15-21.
73. Blom B, Ligthart SJ, Schotte R, et al. Developmental origin of pre-DC2. Hum Immunol. 2002;63:1072-1080.
74. Comeau MR, Van der Vuurst de Vries AR, Maliszewski CR, et al. CD123bright plasmacytoid predendritic cells: progenitors undergoing cell fate conversion? J Immunol. 2002;169:75-83.
75. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
76. Fitzgerald-Bocarsly P. Natural interferon-alpha producing cells: the plasmacytoid dendritic cells. Biotechniques. October 2002;suppl:16-20, 22, 24-29.
77. Manz MG, Traver D, Miyamoto T, et al. Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood. 2001;97:3333-3341.
78. Kondo M, Scherer DC, Miyamoto T, et al. Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. Nature. 2000;407:383-386.
79. Bjorck P, Kincade PW. CD19+ pro-B cells can give rise to dendritic cells in vitro. J Immunol. 1998;161:5795-5799.
80. Izon D, Rudd K, DeMuth W, et al. A common pathway for dendritic cell and early B cell development. J Immunol. 2001;167:1387-1392.
81. Lee CK, Kim JK, Kim Y, et al. Generation of macrophages from early T progenitors in vitro. J Immunol. 2001;166:5964-5969.
82. Olweus J, BitMansour A, Warnke R, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci U S A. 1997;94:12551-12556.
83. Vandenabeele S, Hochrein H, Mavaddat N, et al. Human thymus contains 2 distinct dendritic cell populations. Blood. 2001;97:1733-1741.
84. Galibert L, Maliszewski CR, Vandenabeele S. Plasmacytoid monocytes/T cells: a dendritic cell lineage? Semin Immunol. 2001;13:283-289.
85. Huang Q, Liu D, Majewski P, et al. The plasticity of dendritic cell responses to pathogens and their components. Science. 2001;294:870-875.
86. Ito T, Liu YJ, Kadowaki N. Functional diversity and plasticity of human dendritic cell subsets. Int J Hematol. 2005;81:188-196.
87. Gopcsa L, Banyai A, Jakab K, et al. Extensive flow cytometric characterization of plasmacytoid dendritic cell leukemia cells. Eur J Haematol. 2005;75:346-351.
88. Bene MC, Feuillard J, Jacob MC. Plasmacytoid dendritic cells: from the plasmacytoid T-cell to type 2 dendritic cells CD4+CD56+ malignancies. Semin Hematol. 2003;40:257-266.
89. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000;165:6037-6046.
90. Urosevic M, Conrad C, Kamarashev J, et al. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum Pathol. 2005;36:1020-1024.
91. Carayol G, Robin C, Bourhis JH, et al. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol. 1998;28:1991-2002.
92. Berardi AC, Meffre E, Pflumio F, et al. Individual CD34+CD38lowCD19-CD10- progenitor cells from human cord blood generate B lymphocytes and granulocytes. Blood. 1997;89:3554-3564.
93. Maeda T, Murata K, Fukushima T, et al. A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol. 2005;81:148-154.
94. Schotte R, Rissoan MC, Bendriss-Vermare N, et al. The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development. Blood. 2003;101:1015-1023.
95. Baddoura FK, Hanson C, Chan WC. Plasmacytoid monocyte proliferation associated with myeloproliferative disorders. Cancer. 1992;69:1457-1467.
96. Beiske K, Munthe-Kaas A, Davies CD, et al. Single cell studies on the immunological marker profile of plasmacytoid T-zone cells. Lab Invest. 1987;56:381-393.
97. Muller-Hermelink HK, Stein H, Steinmann G, et al. Malignant lymphoma of plasmacytoid T-cells; morphologic and immunologic studies characterizing a special type of T-cell. Am J Surg Pathol. 1983;7:849-862.
98. Facchetti F, De Wolf-Peeters C, Kennes C, et al. Leukemia-associated lymph node infiltrates of plasmacytoid monocytes (so-called plasmacytoid T-cells): evidence for two distinct histological and immunophenotypical patterns. Am J Surg Pathol. 1990;14:101-112.
99. Baddoura FK, Chan WC. Plasmacytoid acute T-cell lymphoma/leukemia [letter]. Am J Clin Pathol. 1991;96:287-288.
100. Thomas JO, Beiske K, Hann I, et al. Immunohistological diagnosis of "plasmacytoid T cell lymphoma" in paraffin wax sections. J Clin Pathol. 1991;44:632-635.
101. Harris NL, Demirjian Z. Plasmacytoid T-zone cell proliferation in a patient with chronic myelomonocytic leukemia: histologic and immunohistologic characterization. Am J Surg Pathol. 1991;15:87-95.
102. Koo CH, Mason DY, Miller R, et al. Additional evidence that "plasmacytoid T-cell lymphoma" associated with chronic myeloproliferative disorders is of macrophage/monocyte origin. Am J Clin Pathol. 1990;93:822-827.
103. Caldwell CW, Yesus YW, Loy TS, et al. Acute leukemia/lymphoma of plasmacytoid T-cell type. Am J Clin Pathol. 1990;94:778-786.
104. Facchetti F, Vermi W. Plasmacytoid monocytes and plasmacytoid dendritic cells: immune system cells linking innate and acquired immunity [in Italian]. Pathologica. 2002;94:163-175.
105. Mohty M, Isnardon D, Blaise D, et al. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia. 2002;16:2267-2274.
106. Chen YC, Chou JM, Ketterling RP, et al. Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. Am J Clin Pathol. 2003;120:874-881.
107. Karube K, Ohshima K, Tsuchiya T, et al. Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification. Am J Surg Pathol. 2003;27:1366-1374.
108. Yamada O, Ichikawa M, Okamoto T, et al. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. Br J Haematol. 2001;113:153-160.
109. Kazakov DV, Mentzel T, Burg G, et al. Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more? Br J Dermatol. 2003;149:869-876.
110. Kojima H, Bai A, Mukai HY, et al. Chronic myelomonocytic leukemia derived from a possible common progenitor of monocytes and natural killer cells. Leuk Lymphoma. 2000;37:617-621.
111. - progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells. Blood. 1999;93:96-106.
112. Fujii S, Shimizu K, Koji F, et al. Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential. J Leukoc Biol. 2003;73:82-90.
113. Longoni D, D'Amico G, Gaipa G, et al. Commitment of juvenile myelo-monocytic (JMML) leukemic cells to spontaneously differentiate into dendritic cells. Hematol J. 2002;3:302-310.
114. Horny HP, Kaiserling E, Handgretinger R, et al. Evidence for a lymphotropic nature of circulating plasmacytoid monocytes: findings from a case of CD56+ chronic myelomonocytic leukemia. Eur J Haematol. 1995;54:209-216.
115. MacDonald KP, Munster DJ, Clark GJ, et al. Characterization of human blood dendritic cell subsets. Blood. 2002;100:4512-4520.
116. Liu YJ, Kanzler H, Soumelis V, et al. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol. 2001;2:585-589.
117. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.
118. Yang X, Wasserman PG, Bhargava A, et al. Challenge in diagnosis of CD56+ lymphoproliferative disorders: two cases of CD56+CD33+ lymphoma/leukemia. Arch Pathol Lab Med. 2004;128:e100-e103.
119. Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res. 1999;23:615-624.
120. Suzuki R, Yamamoto K, Seto M, et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood. 1997;90:2417-2428.
121. Inaba T, Shimazaki C, Sumikuma T, et al. Clinicopathological features of myeloid/natural killer (NK) cell precursor acute leukemia. Leuk Res. 2001;25:109-113.
122. Inaba T, Shimazaki C, Sumikuma T, et al. Myeloid/natural killer (NK) cell precursor acute leukemia seems not rare among acute myeloid leukemia of M0 subtype (AML-M0) [letter]. Leuk Res. 2000;24:551.
123. Scott AA, Head DR, Kopecky KJ, et al. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood. 1994;84:244-255.